Investigators assessed early predictors of anti-PD-L1 therapy by analysing circulating tumour DNA (ctDNA), and their study showed that a reduction in the frequency of the variant allele was associated with tumour shrinkage after 6 weeks of treatment, providing a valuable non-invasive method for predicting the effectiveness of treatment (44). This evidence concerns the gene CD274 and neoplasm.